Debbie Rigby takes a look at the latest in research news
In this large prospective cohort study apixaban was found to be the safest drug, with reduced risks of major, intracranial, and gastrointestinal bleeding compared with warfarin. Dabigatran was associated with a decreased risk of intracranial bleeding. Rivaroxaban and low dose apixaban were associated with increased risks of all-cause mortality compared with warfarin.
This review summarizes the evidence for the analgesic properties of turmeric and other curcumins. Turmeric has been demonstrated to produce analgesic and anti‐inflammatory effects in animal models and in clinical trials. The authors conclude that Turmeric (curcumin) appears to be a possible candidate for consideration for use as a stand‐alone analgesic, or in analgesic combinations as part of opioid‐, NSAID‐ or paracetamol‐sparing strategies.
J Clin Pharm Ther 2018;43:460–466.
Observational studies suggest that vitamin D deficiency is associated with higher risk of pain. The NZ Vitamin D Assessment study randomised over 5000 community-dwelling patients to receive 100,000 IU capsules monthly for a median of 3.3 years. There was no difference in pain scores or analgesic use assessed at baseline, year 1 or at final follow-up. In patients with a vitamin D deficiency there was a 13% lower risk of dispensing nonsteroidal anti-inflammatory drugs in the vitamin D supplementation group compared with placebo.
Post hoc analysis of the RE-LY study comparing dabigatran 150mg and 110mg twice daily to warfarin in patients with atrial fibrillation has shown an association with increased risk of major bleeding, major gastrointestinal bleeding, stroke/systemic embolism and hospitalisation.
J Am Coll Cardiol. 2018;72:255-267, 268-270.